About PROLASTIN-C LIQUID

A plasma-derived therapy indicated for patients with severe alpha-1 and emphysema1

PROLASTIN-C LIQUID is an alpha₁-proteinase inhibitor (human) indicated for chronic augmentation and maintenance therapy in adults with emphysema due to severe hereditary alpha₁ antitrypsin (AAT) deficiency.¹

Why Augmentation Therapy

Treatment of alpha-1

Augmentation therapy is proven to effectively raise alpha1 antitrypsin (AAT) levels in patients with alpha-1 that help keep neutrophil elastase in check.2 


  • Augmentation therapy is the only treatment specifically approved for adults with emphysema due to severe deficiency of alpha-1 protein.1
  • The intended theoretical goal is to correct the imbalance between neutrophil elastase and AAT.1

How treatment with PROLASTIN-C LIQUID works

Mean plasma AAT concentration vs time following treatment with PROLASTIN-C LIQUID2

Therapy with PROLASTIN-C LIQUID raises AAT levels and antineutrophil elastase activity in the lungs. Maintaining blood serum levels above 11 µM has been postulated to provide protection, although this has not been proven.2

A safety profile trusted for more than 35 years

In clinical trials, the most common adverse reactions (>5%) were diarrhea and fatigue, each in 2 subjects (6%).1

Request a Rep

Four simple steps to start patients on
PROLASTIN-C LIQUID

Screen for Alpha-1

Follow clinical guidelines to screen all patients with COPD and treatment-resistant asthma for alpha-1.

Prescribe PROLASTIN-C LIQUID

Prescribe PROLASTIN-C LIQUID for patients diagnosed with severe alpha-1 and clinical signs of emphysema.1

Enroll in PROLASTIN DIRECT

Complete and fax the simple enrollment form to initiate personalized patient support.

Begin Treatment & Ongoing Support

Enjoy 24/7 access to dedicated infusion support, patient education, and comprehensive care coordination.

About alpha-1

What healthcare providers should know about alpha-1

Learn how a severe hereditary deficiency of alpha1 antitrypsin can lead to an imbalance with neutrophil elastase, resulting in progressive lung damage over time.

About Alpha-1
 
 

Support your patients LIKE A PRO
with PROLASTIN DIRECT®

PROLASTIN-C LIQUID is available through the PROLASTIN DIRECT program.

Enroll Patients

Important Safety Information

PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency). 


Limitations of Use

  • The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials.
  • Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available.
  • PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established.

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

Please see full Prescribing Information for PROLASTIN-C LIQUID.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References

  1. PROLASTIN®-C LIQUID (alpha1-proteinase inhibitor [human]) Prescribing Information. Grifols.
  2. Data on file, Grifols.